Physician profile
Omid Abbassi
NPI 1033279807
$3,245.72
in general payments reported to CMS, 2019-2025
29 companies · $57.93 in 2025
The $57.93 reported for 2025 was less than what a typical Otolaryngology provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $260 · 2020: $477 · 2021: $469 · 2022: $866 · 2023: $1,021 · 2024: $94.96 · 2025: $57.93.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,174.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,174.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Optinose US, INC. | $700.10 | 2020-2024 | |
| Genzyme Corporation | $389.02 | 2020-2023 | |
| Astrazeneca Pharmaceuticals LP | $373.69 | 2020-2023 | |
| Kaleo, INC. | $249.86 | 2020-2023 | Auvi-Q |
| Novartis Pharmaceuticals Corporation | $221.94 | 2019-2024 | |
| Acclarent, INC | $170.95 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $160.28 | 2022-2023 | Cuvitru, Takhzyro |
| Aerin Medical INC. | $123.68 | 2020-2023 | |
| Regeneron Healthcare Solutions, INC. | $103.97 | 2020-2023 | Dupixent |
| Pharming Healthcare, INC. | $87.96 | 2022-2024 | Ruconest |
| Grifols USA, LLC | $76.51 | 2022-2023 | Xembify |
| Glaxosmithkline, LLC. | $75.88 | 2021-2023 | Nucala |
| Blueprint Medicines Corporation | $61.28 | 2023 | Ayvakit |
| Olympus America INC. | $60.55 | 2019-2025 | Rhino-Laryngo Videoscope |
| Amgen INC. | $51.75 | 2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $41.94 | 2021-2022 | |
| Stryker Corporation | $34.08 | 2019 | |
| Biocryst US Sales Co., LLC | $33.97 | 2023 | Orladeyo |
| Genentech USA, INC. | $28.00 | 2023 | Xolair |
| Intersect Ent, INC. | $27.96 | 2021 | |
| Csl Behring | $27.79 | 2023 | Hizentra |
| Alk-Abello, INC | $25.70 | 2020-2021 | |
| Integra Lifesciences Corporation | $22.02 | 2025 | Neuragen |
| Teva Pharmaceuticals USA, INC. | $20.35 | 2021 | |
| Leo Pharma INC. | $18.46 | 2022 | |
| Shire North American Group INC | $17.50 | 2019 | |
| Incyte Corporation | $16.51 | 2022 | |
| Merck Sharp & Dohme LLC | $13.27 | 2021 | |
| Ets Wound Care LLC | $10.75 | 2025 | Mirragen Advanced Wound Matrix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Omid Abbassi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.